Potential Virus Involvement in Alzheimer's Disease: Results from a Phase IIa Trial Evaluating Apovir, an Antiviral Drug Combination.

ABSTRACT:

Background

Accumulating data suggest infectious agents are involved in Alzheimer's disease (AD). The two primary aims of this trial were to assess safety and efficacy of an antiviral drug combination on AD progression.

Objective

The trial evaluated whether Apovir, a combination of two antiviral agents, pleconaril (active on enteroviruses) and ribavirin (active on several viruses), could slow AD progression.

Methods

Sixty-nine patients 60-85 years were treated with Apovir or placebo for 9 months and followed until 12 months after end of treatment. Cognitive tests, safety, biomarkers, drug plasma, and cerebrospinal fluid concentrations were assessed.

Results

The tolerability of Apovir was compromised as demonstrated by the large drop-out rate and increased freque

SUBMITTER: Lindblom N 

PROVIDER: S-EPMC8203284 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature